Lawsuit Claims Abbott Sales Reps Practiced Medicine Without a License While Adjusting Spinal Cord Stimulator
A South Carolina woman has filed a product liability lawsuit against Abbott Laboratories, alleging that unlicensed sales representatives practiced medicine without a license by repeatedly reprogramming her failed Proclaim spinal cord stimulator (SCS) rather than recommending its removal. The plaintiff, Tonia Holley, endured years of pain and electric shocks, only to discover later that the device's leads had migrated, making reprogramming futile. This lawsuit will join other similar Abbott SCS implant lawsuits in a multidistrict litigation (MDL).
Glens Falls BD plant marks 85 years, gives $10,000 to charity
The BD Glens Falls plant is celebrating 85 years of manufacturing essential medical devices, having grown from 35 employees in 1941 to about 550 associates today. To mark the occasion, the company donated $10,000 to the Open Door Mission, an organization that provides food and shelter for those experiencing homelessness and poverty in the region. The anniversary highlights the plant's long-standing contribution to American healthcare and its local community.
BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY
BD (Becton, Dickinson and Company) is celebrating the 85th anniversary of its manufacturing site in Glens Falls, New York. The facility, which started with 35 employees in 1941, now employs approximately 550 associates and produces 6.5 million essential medical devices annually across various care areas. This milestone highlights the site's long-standing contribution to American healthcare resilience and its deep partnership within the local community.
BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY
BD (Becton, Dickinson and Company) is celebrating the 85th anniversary of its manufacturing site in Glens Falls, New York. Founded in 1941, the site employs approximately 550 associates who produce 6.5 million essential medical devices annually, contributing significantly to American healthcare resilience. To mark the occasion, BD donated $10,000 to the Open Door Mission and highlighted its broader community engagement efforts.
BD Named to TIME's 2027 List of America's Top Manufacturers
BD (Becton, Dickinson and Company) has been recognized on TIME's 2027 list of America's Top Manufacturers, highlighting its leadership in U.S. healthcare manufacturing. The company, which is the largest manufacturer of essential medical consumables in the nation, was selected based on its financial performance, innovation capacity, and employment contributions. This marks the second TIME recognition for BD in 2026, following its inclusion in America's Best Companies list earlier in the year.
BD Named to TIME's 2027 List of America's Top Manufacturers
BD (Becton, Dickinson and Company) has been recognized on TIME's 2027 list of America's Top Manufacturers, highlighting its leadership in U.S. healthcare manufacturing. This recognition is based on BD's strong financial performance, innovation capacity, and significant employment contributions. The company, which produces essential medical consumables used in approximately 90% of U.S. hospital visits, continues to invest in its U.S. manufacturing facilities and capabilities.
BD Named to TIME's 2027 List of America's Top Manufacturers
BD (Becton, Dickinson and Company) has been recognized on TIME's 2027 list of America's Top Manufacturers, highlighting its leadership in U.S. manufacturing for essential medical consumables. The company was selected among 250 top manufacturers based on its financial performance, innovation capacity, and employment impact. This marks the second TIME recognition for BD this year, following its inclusion on the 2026 list of America's Best Companies.
Systech Expands Pharmaceutical Manufacturing Offering with Automated Serialization Stations for High-Performance Packaging Lines
Systech has launched two new automated serialization stations, the ST33 and ST34, designed for pharmaceutical manufacturers to enhance packaging line productivity and reduce operational complexity. These systems integrate critical processes like printing, verification, and tamper-evident sealing, running on Systech UniSeries® software. The ST33 is for space-constrained lines, while the ST34 combines multiple functions, aiming to improve efficiency and compliance in pharmaceutical packaging.
CTSO - Cytosorbents Corp Latest SEC Filings
This article provides a detailed overview of Cytosorbents Corp (CTSO), including its latest SEC filings, stock performance, and key financial metrics. It covers various data points such as market capitalization, enterprise value, income, sales, earnings per share, and insider/institutional ownership. The information aims to give investors a comprehensive snapshot of the company's current financial health and market position.
Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push
Danaher (NYSE:DHR) is pursuing accelerated core growth and market-share expansion through a focus on commercial execution, innovation, and strategic acquisitions, according to company leader Julie. The company is directing its substantial annual innovation budget toward high-growth opportunities, leveraging AI for increased productivity, and seeing significant opportunities in diagnostics and bioprocessing. Acquisitions remain a top priority, with over $11 billion deployed this year, expected to yield strong returns.
Insulin Delivery Devices Market to Reach US$ 43.11 Billion
The global insulin delivery devices market is projected to grow from US$ 22.04 billion in 2025 to US$ 43.11 billion by 2033, exhibiting an 8.8% CAGR, driven by the increasing prevalence of diabetes and technological advancements. North America leads the market with a 43.50% share, while Asia-Pacific is expected to experience the fastest growth. Key players like Medtronic, Insulet Corporation, and Tandem Diabetes Care are innovating with smart pens, automated insulin delivery systems, and wearable devices to improve diabetes management.
HLTH 2026: American Hospital Association, West Health Institute announce new collaboration with BD
The American Hospital Association (AHA) and West Health Institute have partnered with medtech company Becton, Dickinson and Company (BD) to accelerate the adoption of technologies that improve patient care. This collaboration, building on the West Health Accelerator at AHA’s HRET, will initially focus on 10 hospitals to integrate advanced physiologic monitoring and clinical protocols to address postoperative complications and long hospital stays. The initiative aims to identify barriers and refine implementation for broader expansion, with Vizient providing performance benchmarking.
BD, Pharmatrade launch UAE's first robot-automated retail pharmacy
BD (Becton, Dickinson and Company) and Pharmatrade have launched the United Arab Emirates' first robot-automated retail pharmacy in Dubai's Wafi Mall. The new pharmacy utilizes BD's Rowa pharmacy automation system for medication storage, retrieval, and inventory management, aiming to increase efficiency, reduce errors, and improve customer service. This installation will also serve as a reference site to demonstrate the potential of robotic medication management in pharmacies across the UAE and the wider region.
AHA, West Health announce collaboration with BD to increase innovation in hospitals and health systems
The American Hospital Association (AHA) and West Health Institute have partnered with Becton, Dickinson and Company (BD) to accelerate the adoption of innovative technologies in hospitals. The initiative will start with a cohort of 10 hospitals integrating advanced physiologic monitoring, with Vizient providing benchmarking and analytics. This collaboration aims to identify adoption barriers, refine implementation, and ultimately expand the model to improve patient outcomes and support care teams.
Omnipod 5 Wrongful Death Lawsuit Alleges Insulin Pump Overdose Caused Fatal Brain Injury
A Connecticut woman has filed a wrongful death lawsuit against Insulet Corporation, claiming that a defective Omnipod 5 insulin pump led to her relative's fatal brain injury. The lawsuit alleges that the device lacked adequate safety features to prevent dangerously high insulin delivery settings, resulting in severe hypoglycemia, coma, and eventually death for Leslie Ann Silvernail. The complaint highlights Insulet's own warnings about incorrect programming and seeks compensatory damages for negligence.
3 US Defensive Dividend Stocks For Higher Rates and Steady Cash Flow
This article identifies three US large-cap defensive dividend stocks – Elevance Health (ELV), Becton Dickinson (BDX), and Cigna Group (CI) – that are well-positioned for an environment of higher interest rates due to their steady cash flows and essential services. These companies operate in healthcare, providing recurring revenue through premiums, medical supplies, and pharmacy benefits, which support consistent dividend payments. The analysis also briefly touches on potential challenges each company might face, such as rising utilization costs or pricing pressures.
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Becton Dickinson & Co. (BDX) shares rose 1.08% to $218.03 on Friday, marking its third consecutive day of gains. This performance occurred on a mixed trading day, with the Dow Jones Industrial Average seeing a slight increase while the S&P 500 Index experienced a decline. The company's stock outpaced competitors despite the broader market's mixed results.
Will Raised 2026 Guidance Change TransMedics Group (TMDX) Narrative
TransMedics Group (TMDX) recently raised its full-year 2026 revenue guidance to US$764 million - US$774 million, including contributions from PAD Aviation. While this higher forecast indicates management's confidence in continued procedure demand and service adoption, the article emphasizes that the key challenge remains converting this top-line growth into sustainable profitability amidst pressure on margins from higher operating expenses. The raised guidance reinforces the growth aspect of the investment thesis but also sharpens focus on the company's ability to improve net income and earnings per share.
What JPMorgan Active Value ETF (JAVA) Bought: HCA Leads on Nov. 11
On November 11, 2026, the JPMorgan Active Value ETF (JAVA) was a net buyer, increasing 19 positions while decreasing 103, resulting in net sales of $102.4 million across its $7.61 billion fund. Its largest purchases by dollar value included HCA Healthcare ($20.0 million), Becton Dickinson & Co ($15.8 million), and Yum Brands Inc ($11.5 million), while it significantly sold Wells Fargo & Co, Entergy Corp, and Chevron Corp. The fund maintains a diversified portfolio with technology, financial services, and healthcare as its top sectors, holding 121 stocks primarily in large-cap companies.
Azitra, Inc. (AZTR) stock price, news, quote and history
Azitra, Inc. (AZTR) is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology. The company's stock shows significant volatility and negative returns across various timeframes, with a current price of $0.6685. Azitra is currently developing several treatments for skin diseases, including ATR-04 for cancer patient rash, ATR-12 for Netherton syndrome, and ATR-01 for ichthyosis vulgaris, and has a joint development agreement with Bayer.
CNSY - Cerenome Inc. stock news, filings & ratings | Quantisnow
Cerenome Inc. (CNSY) is a CNS oncology company listed on NASDAQ, specializing in precision diagnostics, targeted therapeutics, and AI for central nervous system cancers. The company's stock recently saw a significant jump (+46.65%) and has been active with news including a new Chief Business Officer appointment, an in-network agreement with Aetna for its CNSide® Diagnostics platform, and an upcoming conference call to discuss clinical data and Q3 2026 financial results. Financially, Cerenome reported $4.20M in revenue for the last twelve months and a net loss of $26.09M.
Ryder System, Inc. (R) Stock Forecasts
This article provides a brief overview of Ryder System, Inc. (R) stock forecasts, highlighting an Argus report published on November 11, 2026. The report covers the company's industrial sector, current price, and price target, alongside a summary of its Fleet Management Solutions and Supply Chain business segments. The article also mentions related reports on other companies like FedEx and Union Pacific Corp.
Becton Dickinson stock hits 52-week high at 216.85 USD
Becton Dickinson (BDX) stock reached a new 52-week high of $216.85, reflecting robust performance and investor confidence with a 41.96% increase over the past year. InvestingPro analysis suggests the stock is undervalued with a Fair Value of $244.35, indicating potential for further growth. This milestone follows strong fiscal fourth-quarter results and positive analyst upgrades from Jefferies and Wells Fargo.
A director holds 756 stock rights at Becton Dickinson (BDX) after a compensation-plan acquisition.
Becton Dickinson & Co. director Robert Luther Huffines acquired 158 rights to common stock under the BD Deferred Compensation Plan on November 6, 2026, at a price of $197.88 per right. After this transaction, his reported position increased to 756 rights, which includes rights obtained through dividend reinvestment. These rights convert to common stock on a one-for-one basis and are distributed upon the termination of his directorship or on specified dates.
$1.77B in Q3 revenue at Waters (WAT) came with a drop in profit.
Waters Corporation (WAT) reported a significant increase in Q3 2026 revenue to $1.77 billion, up from $800 million in the prior-year quarter, primarily driven by the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions (BDS) business. However, net income for the quarter fell to $81 million from $149 million, and for the first nine months, the company reported a net loss of $127 million compared to a net income of $417 million a year earlier. The decline in profit was largely due to acquisition-related costs, including purchased intangibles amortization, inventory and fixed asset step-up expenses, and restructuring charges from a workforce reduction.
The one who helps breakthroughs happen
Sophie, a sector lead with Aviva Capital Partners, is instrumental in developing the London Cancer District in Sutton, a £1 billion project designed to foster medical innovation. This initiative aims to create a world-leading hub for cancer research and treatment, providing extensive space for businesses, supporting thousands of jobs, and significantly contributing to the UK economy. Sophie's role involves building relationships and securing sites, driven by a personal history of resilience due to a childhood health condition.
Sanofi Uses Movement and Music to Step Ahead of Type 1 Diabetes — LBB
Sanofi has launched a social-first campaign, directed by Adi Halfin and produced by Lief, to encourage early screening for Type 1 diabetes (T1D) among families with a history of the condition. The campaign uses movement, music, and a distinctive finger-point gesture to highlight the simplicity and importance of a finger-prick test, aiming to empower families to take proactive steps rather than waiting for symptoms. This creative approach transforms a clinical necessity into an accessible symbol of empowerment, offering valuable knowledge and time for early intervention strategies.
BD to Host Investor Day on December 10, 2026
BD (Becton, Dickinson and Company) announced it will host an Investor Day for institutional investors and financial analysts on Thursday, December 10, 2026, in New York, NY. The event will feature discussions on the company's business strategy, capital deployment priorities, and long-term outlook by Chairman, CEO, and President Tom Polen, CFO Vitor Roque, and other leadership team members. Attendees can also visit BD's Product Showcase highlighting innovations.
Form 4 Becton Dickinson and Co: Thomas E. Polen Jr (Director, Chairman, CEO and President) For: 5 November
This article reports on a Form 4 filing for Becton Dickinson and Co, indicating an insider transaction by Thomas E. Polen Jr, who holds multiple leadership roles including Director, Chairman, CEO, and President. The filing pertains to activity on November 5th. This type of filing provides transparency regarding changes in ownership by company insiders.
Form 4 Becton Dickinson and Co: Thomas E. Polen Jr (Director, Chairman, CEO and President) For: 5 November
This article reports on a Form 4 filing for Becton Dickinson and Co, detailing a transaction made by Thomas E. Polen Jr, who holds the titles of Director, Chairman, CEO, and President. The filing pertains to an event that occurred on November 5. The article provides the basic information from the regulatory filing without further elaboration.
At $210 per share, Becton Dickinson (BDX) CEO Thomas E. Polen Jr. sells 2,993 shares.
Becton Dickinson (BDX) Chairman, CEO, and President Thomas E. Polen Jr. exercised stock appreciation rights for 20,239 common shares on November 5, 2026, at an exercise price of $178.94 per share. He subsequently returned 17,246 shares to the issuer and sold 2,993 shares, both at $210 per share. These transactions were conducted under a Rule 10b5-1 plan adopted on March 2, 2026.
Will Raised Guidance Change Waters (WAT) Narrative
Waters Corporation (WAT) recently reported strong Q3 2026 sales and net income, alongside raised full-year guidance. This optimism is partly driven by the launch of AI Powered Peak Integration in its Empower Software, which aims to automate chromatography workflows and improve efficiency in regulated labs. The article explores how this new technology and the increased guidance fit into Waters' investment narrative, emphasizing potential growth and profitability levers despite integration risks and market challenges.
Topical Hemostatic Agents Market Size, Share & Forecast 2036
The topical hemostatic agents market is projected to grow from USD 3.37 billion in 2026 to USD 6.3 billion by 2036, at a CAGR of 6.5%. This growth is driven by increasing surgical procedures and the need for specialized bleeding control materials. Gelatin-based products, surgical wound care applications, and hospitals are expected to remain the dominant segments, with the UK, Japan, and Brazil showing the highest growth rates.
Axogen (AXGN) Raised Its 2026 Outlook, Is The Upside Already Priced In?
Axogen (AXGN) has seen a significant stock rally following strong third-quarter results, raised 2026 revenue guidance, and an update on its prostate program. Despite a 30-day return of 38.44% and a year-to-date gain of 61.35%, Simply Wall St's analyst consensus suggests the stock is still 13% undervalued based on a fair value of $57.73. However, a high P/S ratio of 11.2x compared to sector averages raises questions about whether the good news is already reflected in the price, especially given its reliance on a biologic-driven nerve repair portfolio.
3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years
This article highlights three medical device companies—Abbott Laboratories, Stryker, and Becton Dickinson—known for consistently increasing their dividends due to the stable demand for their products. Becton Dickinson stands out with 55 consecutive years of dividend raises, while Abbott boasts 54 years and a commitment to further increases. Stryker, despite a lower yield, has the most room for future dividend growth given its low payout ratio.
West Pharmaceutical Services (WST) Raises 2026 Outlook On Earnings Strength As Fair Value Debate Builds
West Pharmaceutical Services (WST) reported strong third-quarter results, including higher sales and net income, leading to an upgraded 2026 outlook and share repurchases. The company's stock has seen significant short-term gains, with a 30-day return of 9.09% and a year-to-date return of 44.65%. While analysts suggest the stock is 15% undervalued with a fair value of $471, its P/E ratio of 43.6x is above the industry average and an estimated fair ratio of 24.5x, raising questions about its current valuation.
This Centrus Energy Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
A Benzinga article highlights top analyst upgrades for Friday, November 6, 2026. Roth Capital upgraded Centrus Energy (NYSE: LEU) to Buy with a $115 price target. Other companies receiving upgrades include SiTime Corp (NASDAQ: SITM), MGE Energy Inc (NASDAQ: MGEE), Steven Madden Ltd (NASDAQ: SHOO), and Becton Dickinson and Co (NYSE: BDX).
Buy, Sell, or Hold? Friday's Top Upgrades and Downgrades: Becton Dickinson, BJ's Wholesale Club, Cogent Communications, Fervo Energy, JinkoSolar, Molson-Coors, Pfizer, SiTime, Steven Madden, and More
This article details Friday's top Wall Street analyst upgrades, downgrades, and initiations, following a significant market sell-off driven by concerns over AI and data center spending. Analysts adjusted ratings for companies like Becton Dickinson, SiTime, Molson Coors, BJ's Wholesale Club, and Pfizer, among others, identifying new opportunities and shifting recommendations. The report also covers broader market performance, noting the Nasdaq re-entering correction territory and investors seeking technology bargains.
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
Amid persistent market volatility driven by inflation concerns and fears of an AI slowdown, this article highlights three dividend-paying stocks that could offer stability and income. Becton, Dickinson and Company (BDX), Cencora, Inc. (COR), and UniFirst Corporation (UNF) are featured, each having recently announced dividend hikes and demonstrating a history of consistent dividend growth. The piece also touches on recent market crashes and the Federal Reserve's actions to combat inflation.
Becton, Dickinson and Company Q4 Earnings Call Highlights
Becton, Dickinson and Company (BDX) reported higher fiscal fourth-quarter revenue and adjusted earnings, driven by demand for patient monitoring and biologic drug delivery products, offsetting challenges with its Alaris infusion platform. The company provided a fiscal 2027 outlook projecting low-single-digit revenue growth and adjusted EPS of $13.10 to $13.30, with an anticipated return to mid-single-digit growth beyond 2027 as Alaris comparisons fade. BD also highlighted a new agreement with the U.S. government for domestic investment, potentially offering relief from future Section 232 tariffs.
Becton, Dickinson Raises Quarterly Dividend 1% to $1.06 Per Share
Becton, Dickinson and Company has increased its quarterly dividend by 1% to $1.06 per share, resulting in an indicated annual rate of $4.24. The payment is scheduled for December 31, with December 10 designated as both the record and ex-dividend date. This adjustment raises the dividend from the previous $1.05 per share and offers a forward yield of 2.03%.
Becton Dickinson and (BDX) Stock Price, Chart & Analysis
This article provides a comprehensive analysis of Becton Dickinson and Company (BDX) stock, including its latest price, market capitalization, dividend yield, and growth figures. It also presents a quality score, valuation insights, and a "Belegger score" based on Buffett and Lynch methods, offering various scenarios for expected future performance. The report emphasizes that the information is for informational purposes and not investment advice.
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
BD (Becton, Dickinson and Company) announced strong financial results for its fiscal 2026 fourth quarter and full year, ending September 30, 2026, with Q4 revenue increasing 5.4% to $5.3 billion and full-year revenue up 4.9% to $19.5 billion. The company reported significant growth in GAAP and adjusted diluted EPS and free cash flow, while also providing positive fiscal 2027 guidance. Key business highlights included a $19 billion partnership with the U.S. Government for domestic manufacturing, the deployment of its BD Vmax 160 Pharmacy Automation Robot, and advancements in peripheral vascular and advanced tissue regeneration innovations.
Ingredion Cuts 2026 Adjusted EPS Forecast to $9.70
Ingredion reported a 1% year-over-year decline in third-quarter 2026 net sales to $1.792 billion, with adjusted diluted EPS falling to $2.28 from $2.75. The company lowered its 2026 adjusted diluted EPS forecast to $9.25–$9.70, attributing the decrease to higher input costs, softer demand, and slower financial recovery. Despite the decline, Ingredion increased its quarterly dividend to $0.83 per share.
Becton Dickinson Enters Fiscal 2027 With More Focused Portfolio for Sustainable Growth
Becton Dickinson (BDX) reported strong fourth-quarter results, exceeding analyst expectations with adjusted earnings of $4.15 per share and sales of $5.274 billion. The company highlighted broad-based growth across all its businesses and announced its 55th consecutive annual dividend increase. BD also provided a fiscal 2027 adjusted earnings outlook of $13.10 to $13.30 per share, expressing confidence in its focused portfolio and long-term growth trajectory.
[Becton, Dickinson and Q4 2026 Earnings Call] BD Posts 27% EPS Jump to $4.15 as Medtech Pure-Play Debuts; FY2027 Guide of $13.10-$13.30 Disappoints as Alaris Headwind Looms
Becton, Dickinson and Company (BD) reported strong fourth-quarter 2026 results with a 27.3% surge in adjusted diluted EPS to $4.15 and 5.6% FX-neutral revenue growth, completing its first year as a medtech pure-play. However, the company's fiscal 2027 guidance for low single-digit revenue growth and $13.10-$13.30 adjusted EPS disappointed analysts, primarily due to an Alaris capital comparison headwind. Management defended the outlook as "responsible and prudent" while outlining strategic investments and a landmark partnership with the U.S. government.
Privia Health Raises 2026 Revenue Guidance to $2.55B
Privia Health (NASDAQ:PRVA) reported a strong third quarter in 2026, with revenue climbing 13.2% to $657 million and net income soaring 96.6% to $13.5 million. The company has raised its full-year 2026 revenue guidance to $2.50 billion–$2.55 billion and adjusted EBITDA guidance to $154 million–$157 million, following a $36 million acquisition of American Choice Healthcare MSSP. Privia also announced an exit from its Montana partnership, expecting no material impact on 2027 adjusted EBITDA.
Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue Estimates
Becton Dickinson (BDX) reported Q4 earnings of $4.15 per share, exceeding the Zacks Consensus Estimate of $4.06, and revenues of $5.27 billion, surpassing estimates by 2.96%. The company has consistently beaten EPS and revenue estimates over the last four quarters. Despite underperforming the S&P 500 year-to-date, the stock holds a Zacks Rank #2 (Buy), indicating potential for market outperformance.
MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
McKesson Corporation (MCK) reported strong second-quarter fiscal 2027 results, surpassing analyst estimates for both adjusted EPS and revenue. The company saw an 18% increase in adjusted EPS to $11.68 and an 8% rise in revenues to $110.96 billion, driven by specialty distribution growth and higher prescription volumes, particularly for GLP-1 medications. Following this strong performance, McKesson raised its fiscal 2027 adjusted EPS guidance, reflecting confidence in its operational momentum and strategic acquisitions.
BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
BD (Becton, Dickinson and Company) has announced a quarterly dividend increase of 1.0% to $1.06 per common share, marking the 55th consecutive fiscal year the company has raised its dividend. The board also authorized the repurchase of an additional 10 million shares of BD common stock. These actions reflect the company's confidence in its long-term outlook and commitment to returning capital to shareholders.